Director/PDMR Shareholding

    June 30, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
    that Ordinary Shares ("Shares") and American Depositary Shares ("ADSs") in the
    Company, as set out below, have been acquired today for the Non-Executive
    Directors, being the part of their total fees that are paid in shares for the
    period of service from April 1 to June 30, 2016.

                        Type of Security (1)    Number of Shares/ADSs 
                                                                      
    Dominic Blakemore          Shares                      150        
                                                                      
    Olivier Bohuon             Shares                      134        
                                                                      
    William Burns              Shares                      190        
                                                                      
    Gail Fosler                 ADSs                        13        
                                                                      
    Dr. Steven Gillis           ADSs                        61        
                                                                      
    Dr. David Ginsburg          ADSs                        57        
                                                                      
    Susan Kilsby                ADSs                       189        
                                                                      
    Sara Mathew                 ADSs                        54        
                                                                      
    Anne Minto                 Shares                      179        
                                                                      
    Albert Stroucken            ADSs                        17        

    (1)                One ADS is equal to three Shares.

    The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ
    respectively at £44.6306 per Share and $182.7877 per ADS.

    This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)
    of the Disclosure Rules and Transparency Rules.

    Oliver Strawbridge
    Senior Assistant Company Secretary

    For further information please contact:

    Investor Relations                                                           
                                                                                 
    Sarah Elton-Farr                    seltonfarr@shire.com   +44 1256 894157   

    NOTES TO EDITORS

    Shire is the leading global biotechnology company focused on serving people
    with rare diseases and other highly specialized conditions. We strive to
    develop best-in-class products, many of which are available in more than 100
    countries, across core therapeutic areas including Hematology, Immunology,
    Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine
    / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an
    emerging, innovative pipeline in Ophthalmics.

    Our employees come to work every day with a shared mission: to develop and
    deliver breakthrough therapies for the hundreds of millions of people in the
    world affected by rare diseases and other high-need conditions, and who lack
    effective therapies to live their lives to the fullest.

    www.shire.com